Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CapForce Inc.OPGN · Entity 9776 | Director | May 17, 2021 | May 19, 2021 |
| STANDARD BIOTOOLS INC.FLDM · Entity 6116 | Director | July 31, 2017 | August 03, 2017 |
| VERACYTE, INC.VCYT · Entity 2018 | Director | June 11, 2026 | June 15, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CapForce Inc.
Report date May 17, 2021 · Filed May 19, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 22,617 |
Reported balance
After 2021-05-17 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2021-05-17 · Exercise / conversion · Acquired 883 · Balance 22,617 F1: All stock information is adjusted to reflect a twenty-five-to-one reverse stock split effected on August 29, 2019. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 884 |
Reported balance
After 2021-05-17 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-05-17 · Exercise / conversion · Disposed 883 · Balance 884 F1: All stock information is adjusted to reflect a twenty-five-to-one reverse stock split effected on August 29, 2019. F2: Represents vesting of restricted stock units ("RSUs") granted in May 2019 that convert into common stock on a one-for-one basis. F3: On May 17, 2019, the Reporting Person was granted 2,650 RSUs (on a post-stock split basis). The RSUs were granted subject to forfeiture, which forfeiture restrictions will lapse as to one-third of the award on the first, second and third anniversaries of the date of grant, subject to acceleration as set forth in the Reporting Person's employment agreement with the Registrant. |
Filing footnotes · ownership attribution and instrument terms
F1: All stock information is adjusted to reflect a twenty-five-to-one reverse stock split effected on August 29, 2019.
F2: Represents vesting of restricted stock units ("RSUs") granted in May 2019 that convert into common stock on a one-for-one basis.
F3: On May 17, 2019, the Reporting Person was granted 2,650 RSUs (on a post-stock split basis). The RSUs were granted subject to forfeiture, which forfeiture restrictions will lapse as to one-third of the award on the first, second and third anniversaries of the date of grant, subject to acceleration as set forth in the Reporting Person's employment agreement with the Registrant.
STANDARD BIOTOOLS INC.
Report date July 31, 2017 · Filed August 03, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy jVen Capital, LLC | 58,551 |
Reported balance
After 2017-07-31 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2017-07-31 · Exercise / conversion · Acquired 5,000 · Balance 58,551 F1: The reporting person is managing member of jVen Capital, LLC. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Expires 2017-07-31 | Direct | 0 |
Reported balance
After 2017-07-31 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2017-07-31 · Exercise / conversion · Disposed 5,000 · Balance 0 F2: Each Restricted Stock Unit represents the contingent right to receive one share of FLDM common stock upon vesting of the unit. |
Filing footnotes · ownership attribution and instrument terms
F1: The reporting person is managing member of jVen Capital, LLC.
F2: Each Restricted Stock Unit represents the contingent right to receive one share of FLDM common stock upon vesting of the unit.
VERACYTE, INC.
Report date June 11, 2026 · Filed June 15, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 34,634 |
Reported balance
After 2026-06-11 transaction · row 1
1 source rowRow 1 · 2026-06-11 · Grant · Acquired 5,272 · Balance 34,634 F1: Restricted stock units awarded on June 11, 2026 vest in full on the first anniversary of the date of the grant or immediately prior to the Company's next annual meeting of stockholders, if earlier. In addition, the restricted stock units vest in full in the event of a change in control of the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: Restricted stock units awarded on June 11, 2026 vest in full on the first anniversary of the date of the grant or immediately prior to the Company's next annual meeting of stockholders, if earlier. In addition, the restricted stock units vest in full in the event of a change in control of the Issuer.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Foundation Medicine, Inc.
Report date July 31, 2018 · Filed August 02, 2018
Section 16 reporting ended · disclosed 2018-08-02. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2018-07-31 transaction · row 1
1 source rowRow 1 · 2018-07-31 · Other · Disposed 17,652 · Balance 0 F1: Foundation Medicine, Inc., a Delaware corporation (the "Company") entered into an Agreement and Plan of Merger, dated as of June 18, 2018, as amended (the "Merger Agreement"), with Roche Holdings, Inc., a Delaware corporation ("Parent" or "Roche"), and 062018 Merger Subsidiary, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Parent caused Merger Sub to conduct a tender offer (the "Tender Offer") for all of the issued and outstanding shares of common stock, par value $0.0001 per share, of the Company, at a price of $137 per share. On July 31, 2018, Merger Sub irrevocably accepted for payment all shares that were validly tendered and not withdrawn. On July 31, 2018, following consummation of the Tender Offer, Merger Sub merged with and into the Company. F2: The amount reported represents the number of shares sold by the reporting person in connection with the Tender Offer by Roche. |
| Common StockSEC Table I · non-derivative | Indirectby jVen Capital LLC | 0 |
Reported balance
After 2018-07-31 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2018-07-31 · Other · Disposed 9,300 · Balance 0 F1: Foundation Medicine, Inc., a Delaware corporation (the "Company") entered into an Agreement and Plan of Merger, dated as of June 18, 2018, as amended (the "Merger Agreement"), with Roche Holdings, Inc., a Delaware corporation ("Parent" or "Roche"), and 062018 Merger Subsidiary, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Parent caused Merger Sub to conduct a tender offer (the "Tender Offer") for all of the issued and outstanding shares of common stock, par value $0.0001 per share, of the Company, at a price of $137 per share. On July 31, 2018, Merger Sub irrevocably accepted for payment all shares that were validly tendered and not withdrawn. On July 31, 2018, following consummation of the Tender Offer, Merger Sub merged with and into the Company. F3: The amount reported represents the number of shares sold by the reporting person in connection with the tender offer for shares of Common Stock of the Issuer (the "Tender Offer") by Roche Holdings, Inc. ("Roche"). |
| stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.16 · Expires 2023-03-07 | Direct | 0 |
Reported balance
After 2018-07-31 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2018-07-31 · Other · Disposed 6,252 · Balance 0 F1: Foundation Medicine, Inc., a Delaware corporation (the "Company") entered into an Agreement and Plan of Merger, dated as of June 18, 2018, as amended (the "Merger Agreement"), with Roche Holdings, Inc., a Delaware corporation ("Parent" or "Roche"), and 062018 Merger Subsidiary, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Parent caused Merger Sub to conduct a tender offer (the "Tender Offer") for all of the issued and outstanding shares of common stock, par value $0.0001 per share, of the Company, at a price of $137 per share. On July 31, 2018, Merger Sub irrevocably accepted for payment all shares that were validly tendered and not withdrawn. On July 31, 2018, following consummation of the Tender Offer, Merger Sub merged with and into the Company. F4: This option was granted on March 7, 2013 and vested in sixteen equal quarterly installments thereafter, ending on January 10, 2017. |
| stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $24.21 · Expires 2024-06-18 | Direct | 0 |
Reported balance
After 2018-07-31 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2018-07-31 · Other · Disposed 13,385 · Balance 0 F1: Foundation Medicine, Inc., a Delaware corporation (the "Company") entered into an Agreement and Plan of Merger, dated as of June 18, 2018, as amended (the "Merger Agreement"), with Roche Holdings, Inc., a Delaware corporation ("Parent" or "Roche"), and 062018 Merger Subsidiary, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Parent caused Merger Sub to conduct a tender offer (the "Tender Offer") for all of the issued and outstanding shares of common stock, par value $0.0001 per share, of the Company, at a price of $137 per share. On July 31, 2018, Merger Sub irrevocably accepted for payment all shares that were validly tendered and not withdrawn. On July 31, 2018, following consummation of the Tender Offer, Merger Sub merged with and into the Company. |
| stock option (right to buySEC Table II · derivative / convertible security · Conversion / exercise price $7.12 · Expires 2023-05-22 | Direct | 0 |
Reported balance
After 2018-07-31 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2018-07-31 · Other · Disposed 4,922 · Balance 0 F1: Foundation Medicine, Inc., a Delaware corporation (the "Company") entered into an Agreement and Plan of Merger, dated as of June 18, 2018, as amended (the "Merger Agreement"), with Roche Holdings, Inc., a Delaware corporation ("Parent" or "Roche"), and 062018 Merger Subsidiary, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Parent caused Merger Sub to conduct a tender offer (the "Tender Offer") for all of the issued and outstanding shares of common stock, par value $0.0001 per share, of the Company, at a price of $137 per share. On July 31, 2018, Merger Sub irrevocably accepted for payment all shares that were validly tendered and not withdrawn. On July 31, 2018, following consummation of the Tender Offer, Merger Sub merged with and into the Company. F5: This stock option was granted on May 22, 2013 and vested in sixteen equal quarterly installments thereafter, ending on May 22, 2017. |
Filing footnotes · ownership attribution and instrument terms
F1: Foundation Medicine, Inc., a Delaware corporation (the "Company") entered into an Agreement and Plan of Merger, dated as of June 18, 2018, as amended (the "Merger Agreement"), with Roche Holdings, Inc., a Delaware corporation ("Parent" or "Roche"), and 062018 Merger Subsidiary, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Parent caused Merger Sub to conduct a tender offer (the "Tender Offer") for all of the issued and outstanding shares of common stock, par value $0.0001 per share, of the Company, at a price of $137 per share. On July 31, 2018, Merger Sub irrevocably accepted for payment all shares that were validly tendered and not withdrawn. On July 31, 2018, following consummation of the Tender Offer, Merger Sub merged with and into the Company.
F2: The amount reported represents the number of shares sold by the reporting person in connection with the Tender Offer by Roche.
F3: The amount reported represents the number of shares sold by the reporting person in connection with the tender offer for shares of Common Stock of the Issuer (the "Tender Offer") by Roche Holdings, Inc. ("Roche").
F4: This option was granted on March 7, 2013 and vested in sixteen equal quarterly installments thereafter, ending on January 10, 2017.
F5: This stock option was granted on May 22, 2013 and vested in sixteen equal quarterly installments thereafter, ending on May 22, 2017.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 11, 2026 Filed Jun 15, 2026 20:56 UTC | VERACYTE, INC. VCYT · Entity 2018 | GrantCommon Stock | 5,272 | $0.00 | $0.00 |
DisclosureSEC source: 0001020741-26-000002 · wk-form4_1781556970.xml · nonDerivative · entry 1 JONES EVAN/ FA · CIK 0001020741 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,634 F1 · kind: Restricted stock units awarded on June 11, 2026 vest in full on the first anniversary of the date of the grant or immediately prior to the Company's next annual meeting of stockholders, if earlier. In addition, the restricted stock units vest in full in the event of a change in control of the Issuer. Read SEC document |
| November 25, 2025 Filed Nov 26, 2025 21:27 UTC | VERACYTE, INC. VCYT · Entity 2018 | SaleCommon Stock | 1,106 | $50.25 | $55,575.73 |
DisclosureSEC source: 0001020741-25-000006 · wk-form4_1764192433.xml · nonDerivative · entry 1 JONES EVAN/ FA · CIK 0001020741 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 29,362 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on December 9, 2024. F2 · price: Represents weighted average sales price. Sale prices for the transactions range from $50.005 to $50.66. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. Read SEC document |
| November 05, 2025 Filed Nov 7, 2025 21:10 UTC | VERACYTE, INC. VCYT · Entity 2018 | Exercise / conversionStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $7.60 | $0.00 |
DisclosureSEC source: 0001020741-25-000004 · wk-form4_1762549821.xml · derivative · entry 12 JONES EVAN/ FA · CIK 0001020741 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2028-06-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on December 9, 2024. F8 · derivative.exercise_date: The option is fully vested. Read SEC document |
| November 05, 2025 Filed Nov 7, 2025 21:10 UTC | VERACYTE, INC. VCYT · Entity 2018 | Exercise / conversionStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $7.94 | $0.00 |
DisclosureSEC source: 0001020741-25-000004 · wk-form4_1762549821.xml · derivative · entry 11 JONES EVAN/ FA · CIK 0001020741 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2027-06-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on December 9, 2024. F8 · derivative.exercise_date: The option is fully vested. Read SEC document |
| November 05, 2025 Filed Nov 7, 2025 21:10 UTC | VERACYTE, INC. VCYT · Entity 2018 | Exercise / conversionStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $5.28 | $0.00 |
DisclosureSEC source: 0001020741-25-000004 · wk-form4_1762549821.xml · derivative · entry 10 JONES EVAN/ FA · CIK 0001020741 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2026-06-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on December 9, 2024. F8 · derivative.exercise_date: The option is fully vested. Read SEC document |
| November 05, 2025 Filed Nov 7, 2025 21:10 UTC | VERACYTE, INC. VCYT · Entity 2018 | SaleCommon Stock | 657 | $46.38 | $30,468.77 |
DisclosureSEC source: 0001020741-25-000004 · wk-form4_1762549821.xml · nonDerivative · entry 9 JONES EVAN/ FA · CIK 0001020741 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 30,468 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on December 9, 2024. F7 · price: Represents weighted average sales price. Sale prices for the transactions range from $46.35 to $46.40. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. Read SEC document |
| November 05, 2025 Filed Nov 7, 2025 21:10 UTC | VERACYTE, INC. VCYT · Entity 2018 | SaleCommon Stock | 24,296 | $45.73 | $1,110,990.48 |
DisclosureSEC source: 0001020741-25-000004 · wk-form4_1762549821.xml · nonDerivative · entry 8 JONES EVAN/ FA · CIK 0001020741 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 31,125 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on December 9, 2024. F6 · price: Represents weighted average sales price. Sale prices for the transactions range from $45.34 to $44.33. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. Read SEC document |
| November 05, 2025 Filed Nov 7, 2025 21:10 UTC | VERACYTE, INC. VCYT · Entity 2018 | SaleCommon Stock | 5,872 | $45.07 | $264,640.47 |
DisclosureSEC source: 0001020741-25-000004 · wk-form4_1762549821.xml · nonDerivative · entry 7 JONES EVAN/ FA · CIK 0001020741 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 55,421 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on December 9, 2024. F5 · price: Represents weighted average sales price. Sale prices for the transactions range from $44.335 to $45.335. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. Read SEC document |
| November 05, 2025 Filed Nov 7, 2025 21:10 UTC | VERACYTE, INC. VCYT · Entity 2018 | SaleCommon Stock | 10,837 | $43.80 | $474,701.78 |
DisclosureSEC source: 0001020741-25-000004 · wk-form4_1762549821.xml · nonDerivative · entry 6 JONES EVAN/ FA · CIK 0001020741 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 61,293 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on December 9, 2024. F4 · price: Represents weighted average sales price. Sale prices for the transactions range from $43.29 to $44.29. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. Read SEC document |
| November 05, 2025 Filed Nov 7, 2025 21:10 UTC | VERACYTE, INC. VCYT · Entity 2018 | SaleCommon Stock | 1,126 | $43.03 | $48,455.05 |
DisclosureSEC source: 0001020741-25-000004 · wk-form4_1762549821.xml · nonDerivative · entry 5 JONES EVAN/ FA · CIK 0001020741 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 72,130 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on December 9, 2024. F3 · price: Represents weighted average sales price. Sale prices for the transactions range from $42.285 to $43.20. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. Read SEC document |
| November 05, 2025 Filed Nov 7, 2025 21:10 UTC | VERACYTE, INC. VCYT · Entity 2018 | SaleCommon Stock | 408 | $41.74 | $17,031.18 |
DisclosureSEC source: 0001020741-25-000004 · wk-form4_1762549821.xml · nonDerivative · entry 4 JONES EVAN/ FA · CIK 0001020741 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 73,256 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on December 9, 2024. F2 · price: Represents weighted average sales price. Sale prices for the transactions range from $41.10 to $41.97. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. Read SEC document |
| November 05, 2025 Filed Nov 7, 2025 21:10 UTC | VERACYTE, INC. VCYT · Entity 2018 | Exercise / conversionCommon Stock | 10,000 | $7.60 | $76,000.00 |
DisclosureSEC source: 0001020741-25-000004 · wk-form4_1762549821.xml · nonDerivative · entry 3 JONES EVAN/ FA · CIK 0001020741 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 73,664 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on December 9, 2024. Read SEC document |
| November 05, 2025 Filed Nov 7, 2025 21:10 UTC | VERACYTE, INC. VCYT · Entity 2018 | Exercise / conversionCommon Stock | 10,000 | $7.94 | $79,400.00 |
DisclosureSEC source: 0001020741-25-000004 · wk-form4_1762549821.xml · nonDerivative · entry 2 JONES EVAN/ FA · CIK 0001020741 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 63,664 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on December 9, 2024. Read SEC document |
| November 05, 2025 Filed Nov 7, 2025 21:10 UTC | VERACYTE, INC. VCYT · Entity 2018 | Exercise / conversionCommon Stock | 10,000 | $5.28 | $52,800.00 |
DisclosureSEC source: 0001020741-25-000004 · wk-form4_1762549821.xml · nonDerivative · entry 1 JONES EVAN/ FA · CIK 0001020741 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 53,664 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on December 9, 2024. Read SEC document |
| June 18, 2025 Filed Jun 23, 2025 20:10 UTC | VERACYTE, INC. VCYT · Entity 2018 | GrantCommon Stock | 9,321 | $0.00 | $0.00 |
DisclosureSEC source: 0001384101-25-000097 · wk-form4_1750709409.xml · nonDerivative · entry 1 JONES EVAN/ FA · CIK 0001020741 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,664 F1 · kind: Restricted stock units awarded on June 18, 2025 vest in full on the first anniversary of the date of the grant or immediately prior to the Company's next annual meeting of stockholders, if earlier. In addition, the restricted stock units vest in full in the event of a change in control of the Issuer. Read SEC document |
| September 19, 2024 Filed Sep 23, 2024 20:23 UTC | VERACYTE, INC. VCYT · Entity 2018 | SaleCommon Stock | 5,173 | $35.23 | $182,262.90 |
DisclosureSEC source: 0001384101-24-000155 · wk-form4_1727123023.xml · nonDerivative · entry 1 JONES EVAN/ FA · CIK 0001020741 · Director 10b5-1 filing: Plan reported Ownership: Indirect · by jVen Capital, LLC Disclosed balance after: 0 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on February 28, 2024. F2 · price: Represents weighted average sales price. Sale prices for the transactions range from $35.085 to $35.43. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. F3 · ownership.nature: The Reporting Person is the sole managing member of jVen Capital, LLC. Read SEC document |
| August 13, 2024 Filed Aug 14, 2024 21:09 UTC | VERACYTE, INC. VCYT · Entity 2018 | Exercise / conversionStock Option (right to buy) · Derivative | 8,486 | $0.00 Strike: $10.41 | $0.00 |
DisclosureSEC source: 0001384101-24-000128 · wk-form4_1723669784.xml · derivative · entry 10 JONES EVAN/ FA · CIK 0001020741 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,486 shares Expires 2025-05-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on February 28, 2024. F7 · derivative.exercise_date: The option is fully vested. Read SEC document |
| August 13, 2024 Filed Aug 14, 2024 21:09 UTC | VERACYTE, INC. VCYT · Entity 2018 | SaleCommon Stock | 912 | $32.77 | $29,884.23 |
DisclosureSEC source: 0001384101-24-000128 · wk-form4_1723669784.xml · nonDerivative · entry 9 JONES EVAN/ FA · CIK 0001020741 · Director 10b5-1 filing: Plan reported Ownership: Indirect · by jVen Capital, LLC Disclosed balance after: 5,173 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on February 28, 2024. F6 · price: Represents weighted average sales price. Sale prices for the transactions range from $32.715 to $32.80. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. F3 · ownership.nature: The Reporting Person is the sole managing member of jVen Capital, LLC. Read SEC document |
| August 13, 2024 Filed Aug 14, 2024 21:09 UTC | VERACYTE, INC. VCYT · Entity 2018 | SaleCommon Stock | 22,407 | $32.36 | $725,025.54 |
DisclosureSEC source: 0001384101-24-000128 · wk-form4_1723669784.xml · nonDerivative · entry 8 JONES EVAN/ FA · CIK 0001020741 · Director 10b5-1 filing: Plan reported Ownership: Indirect · by jVen Capital, LLC Disclosed balance after: 6,085 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on February 28, 2024. F5 · price: Represents weighted average sales price. Sale prices for the transactions range from $31.71 to $32.71. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. F3 · ownership.nature: The Reporting Person is the sole managing member of jVen Capital, LLC. Read SEC document |
| August 13, 2024 Filed Aug 14, 2024 21:09 UTC | VERACYTE, INC. VCYT · Entity 2018 | SaleCommon Stock | 3,869 | $31.19 | $120,654.77 |
DisclosureSEC source: 0001384101-24-000128 · wk-form4_1723669784.xml · nonDerivative · entry 7 JONES EVAN/ FA · CIK 0001020741 · Director 10b5-1 filing: Plan reported Ownership: Indirect · by jVen Capital, LLC Disclosed balance after: 28,492 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on February 28, 2024. F4 · price: Represents weighted average sales price. Sale prices for the transactions range from $30.70 to $31.70. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. F3 · ownership.nature: The Reporting Person is the sole managing member of jVen Capital, LLC. Read SEC document |
| August 13, 2024 Filed Aug 14, 2024 21:09 UTC | VERACYTE, INC. VCYT · Entity 2018 | SaleCommon Stock | 688 | $32.77 | $22,544.25 |
DisclosureSEC source: 0001384101-24-000128 · wk-form4_1723669784.xml · nonDerivative · entry 6 JONES EVAN/ FA · CIK 0001020741 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 34,343 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on February 28, 2024. F6 · price: Represents weighted average sales price. Sale prices for the transactions range from $32.715 to $32.80. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. Read SEC document |
| August 13, 2024 Filed Aug 14, 2024 21:09 UTC | VERACYTE, INC. VCYT · Entity 2018 | SaleCommon Stock | 16,838 | $32.36 | $544,850.74 |
DisclosureSEC source: 0001384101-24-000128 · wk-form4_1723669784.xml · nonDerivative · entry 5 JONES EVAN/ FA · CIK 0001020741 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 35,031 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on February 28, 2024. F5 · price: Represents weighted average sales price. Sale prices for the transactions range from $31.71 to $32.71. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. Read SEC document |
| August 13, 2024 Filed Aug 14, 2024 21:09 UTC | VERACYTE, INC. VCYT · Entity 2018 | SaleCommon Stock | 2,931 | $31.19 | $91,405.87 |
DisclosureSEC source: 0001384101-24-000128 · wk-form4_1723669784.xml · nonDerivative · entry 4 JONES EVAN/ FA · CIK 0001020741 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 51,869 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on February 28, 2024. F4 · price: Represents weighted average sales price. Sale prices for the transactions range from $30.70 to $31.70. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. Read SEC document |
| August 13, 2024 Filed Aug 14, 2024 21:09 UTC | VERACYTE, INC. VCYT · Entity 2018 | Exercise / conversionCommon Stock | 8,486 | $10.41 | $88,339.26 |
DisclosureSEC source: 0001384101-24-000128 · wk-form4_1723669784.xml · nonDerivative · entry 3 JONES EVAN/ FA · CIK 0001020741 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 54,800 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on February 28, 2024. Read SEC document |
| August 12, 2024 Filed Aug 14, 2024 21:09 UTC | VERACYTE, INC. VCYT · Entity 2018 | SaleCommon Stock | 101 | $30.01 | $3,030.51 |
DisclosureSEC source: 0001384101-24-000128 · wk-form4_1723669784.xml · nonDerivative · entry 2 JONES EVAN/ FA · CIK 0001020741 · Director 10b5-1 filing: Plan reported Ownership: Indirect · by jVen Capital, LLC Disclosed balance after: 32,361 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on February 28, 2024. F2 · price: Represents weighted average sales price. Sale prices for the transactions range from $30.00 to $30.01. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. F3 · ownership.nature: The Reporting Person is the sole managing member of jVen Capital, LLC. Read SEC document |
| August 12, 2024 Filed Aug 14, 2024 21:09 UTC | VERACYTE, INC. VCYT · Entity 2018 | SaleCommon Stock | 99 | $30.01 | $2,970.50 |
DisclosureSEC source: 0001384101-24-000128 · wk-form4_1723669784.xml · nonDerivative · entry 1 JONES EVAN/ FA · CIK 0001020741 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 46,314 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on February 28, 2024. F2 · price: Represents weighted average sales price. Sale prices for the transactions range from $30.00 to $30.01. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. Read SEC document |
| August 09, 2024 Filed Aug 13, 2024 20:38 UTC | VERACYTE, INC. VCYT · Entity 2018 | Exercise / conversionStock Option (right to buy) · Derivative | 300 | $0.00 Strike: $10.41 | $0.00 |
DisclosureSEC source: 0001384101-24-000126 · wk-form4_1723581436.xml · derivative · entry 4 JONES EVAN/ FA · CIK 0001020741 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,486 Underlying: Common Stock · 300 shares Expires 2025-05-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on February 28, 2024. F4 · derivative.exercise_date: The option is fully vested. Read SEC document |
| August 09, 2024 Filed Aug 13, 2024 20:38 UTC | VERACYTE, INC. VCYT · Entity 2018 | SaleCommon Stock | 746 | $30.03 | $22,401.63 |
DisclosureSEC source: 0001384101-24-000126 · wk-form4_1723581436.xml · nonDerivative · entry 3 JONES EVAN/ FA · CIK 0001020741 · Director 10b5-1 filing: Plan reported Ownership: Indirect · by jVen Capital, LLC Disclosed balance after: 32,462 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on February 28, 2024. F2 · price: Represents weighted average sales price. Sale prices for the transactions range from $30.00 to $30.09. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. F3 · ownership.nature: The Reporting Person is the sole managing member of jVen Capital, LLC. Read SEC document |
| August 09, 2024 Filed Aug 13, 2024 20:38 UTC | VERACYTE, INC. VCYT · Entity 2018 | SaleCommon Stock | 1,032 | $30.03 | $30,989.82 |
DisclosureSEC source: 0001384101-24-000126 · wk-form4_1723581436.xml · nonDerivative · entry 2 JONES EVAN/ FA · CIK 0001020741 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 46,413 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on February 28, 2024. F2 · price: Represents weighted average sales price. Sale prices for the transactions range from $30.00 to $30.09. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. Read SEC document |
| August 09, 2024 Filed Aug 13, 2024 20:38 UTC | VERACYTE, INC. VCYT · Entity 2018 | Exercise / conversionCommon Stock | 300 | $10.41 | $3,123.00 |
DisclosureSEC source: 0001384101-24-000126 · wk-form4_1723581436.xml · nonDerivative · entry 1 JONES EVAN/ FA · CIK 0001020741 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 47,445 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on February 28, 2024. Read SEC document |
| August 07, 2024 Filed Aug 9, 2024 20:47 UTC | VERACYTE, INC. VCYT · Entity 2018 | Exercise / conversionStock Option (right to buy) · Derivative | 1,214 | $0.00 Strike: $10.41 | $0.00 |
DisclosureSEC source: 0001384101-24-000121 · wk-form4_1723236461.xml · derivative · entry 4 JONES EVAN/ FA · CIK 0001020741 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,786 Underlying: Common Stock · 1,214 shares Expires 2025-05-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on February 28, 2024. F4 · derivative.exercise_date: The option is fully vested. Read SEC document |
| August 07, 2024 Filed Aug 9, 2024 20:47 UTC | VERACYTE, INC. VCYT · Entity 2018 | SaleCommon Stock | 5,108 | $30.32 | $154,883.24 |
DisclosureSEC source: 0001384101-24-000121 · wk-form4_1723236461.xml · nonDerivative · entry 2 JONES EVAN/ FA · CIK 0001020741 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 45,180 F2 · price: Represents weighted average sales price. Sale prices for the transactions range from $30.02 to $30.73. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. F1 · acquired: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on February 28, 2024. Read SEC document |
| August 07, 2024 Filed Aug 9, 2024 20:47 UTC | VERACYTE, INC. VCYT · Entity 2018 | Exercise / conversionCommon Stock | 1,214 | $10.41 | $12,637.74 |
DisclosureSEC source: 0001384101-24-000121 · wk-form4_1723236461.xml · nonDerivative · entry 1 JONES EVAN/ FA · CIK 0001020741 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 50,288 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · acquired: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on February 28, 2024. Read SEC document |
| August 07, 2024 Filed Aug 13, 2024 20:37 UTC Amendment | VERACYTE, INC. VCYT · Entity 2018 | SaleCommon Stock | 1,965 | $30.32 | $59,582.14 |
DisclosureSEC source: 0001384101-24-000125 · wk-form4a_1723581424.xml · nonDerivative · entry 2 JONES EVAN/ FA · CIK 0001020741 · Director 10b5-1 filing: Plan reported Ownership: Indirect · by jVen Capital, LLC Disclosed balance after: 33,208 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on February 28, 2024. F2 · price: Represents weighted average sales price. Sale prices for the transactions range from $30.02 to $30.73. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. F3 · ownership.nature: The Reporting Person is the sole managing member of jVen Capital, LLC. Read SEC document |
| August 07, 2024 Filed Aug 13, 2024 20:37 UTC Amendment | VERACYTE, INC. VCYT · Entity 2018 | SaleCommon Stock | 3,143 | $30.32 | $95,301.10 |
DisclosureSEC source: 0001384101-24-000125 · wk-form4a_1723581424.xml · nonDerivative · entry 1 JONES EVAN/ FA · CIK 0001020741 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 47,145 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on February 28, 2024. F2 · price: Represents weighted average sales price. Sale prices for the transactions range from $30.02 to $30.73. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. Read SEC document |
| June 13, 2024 Filed Jun 17, 2024 20:49 UTC | VERACYTE, INC. VCYT · Entity 2018 | GrantCommon Stock | 11,473 | $0.00 | $0.00 |
DisclosureSEC source: 0001384101-24-000105 · wk-form4_1718657345.xml · nonDerivative · entry 1 JONES EVAN/ FA · CIK 0001020741 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 49,074 F1 · kind: Restricted stock units awarded on June 13, 2024 vest in full on the first anniversary of the date of the grant or immediately prior to the Company's next annual meeting of stockholders, if earlier. In addition, the restricted stock units vest in full in the event of a change in control of the Issuer. Read SEC document |
| March 01, 2024 Filed Mar 5, 2024 22:28 UTC | VERACYTE, INC. VCYT · Entity 2018 | Exercise / conversionStock Option (right to buy) · Derivative | 10,000 | $13.19 Strike: $13.19 | $131,900.00 |
DisclosureSEC source: 0001384101-24-000027 · wk-form4_1709677710.xml · derivative · entry 4 JONES EVAN/ FA · CIK 0001020741 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2024-05-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option is fully vested. Read SEC document |
| March 01, 2024 Filed Mar 5, 2024 22:28 UTC | VERACYTE, INC. VCYT · Entity 2018 | SaleCommon Stock | 10,000 | $24.36 | $243,599.00 |
DisclosureSEC source: 0001384101-24-000027 · wk-form4_1709677710.xml · nonDerivative · entry 2 JONES EVAN/ FA · CIK 0001020741 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,601 F1 · price: Represents weighted average sales price. Sale prices for the transactions range from $24.24 to $24.45. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. Read SEC document |
| March 01, 2024 Filed Mar 5, 2024 22:28 UTC | VERACYTE, INC. VCYT · Entity 2018 | Exercise / conversionCommon Stock | 10,000 | $13.19 | $131,900.00 |
DisclosureSEC source: 0001384101-24-000027 · wk-form4_1709677710.xml · nonDerivative · entry 1 JONES EVAN/ FA · CIK 0001020741 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,601 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 19, 2023 Filed Jul 24, 2023 21:06 UTC | VERACYTE, INC. VCYT · Entity 2018 | SaleCommon Stock | 3,090 | $30.17 | $93,232.41 |
DisclosureSEC source: 0001384101-23-000134 · wk-form4_1690232803.xml · nonDerivative · entry 2 JONES EVAN/ FA · CIK 0001020741 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · by jVen Capital, LLC Disclosed balance after: 35,173 F4 · price: Represents weighted average sales price. Sale prices for the transactions range from $30.01 to $30.28. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. F3 · acquired: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on December 12, 2022. F5 · ownership.nature: The Reporting Person is the sole managing member of jVen Capital, LLC. Read SEC document |
| July 19, 2023 Filed Jul 24, 2023 21:06 UTC | VERACYTE, INC. VCYT · Entity 2018 | SaleCommon Stock | 838 | $30.14 | $25,257.15 |
DisclosureSEC source: 0001384101-23-000134 · wk-form4_1690232803.xml · nonDerivative · entry 1 JONES EVAN/ FA · CIK 0001020741 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,601 F2 · price: Represents weighted average sales price. Sale prices for the transactions range from $30.01 to $30.26. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. F1 · acquired: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on June 11, 2022. Read SEC document |
| July 18, 2023 Filed Jul 20, 2023 00:33 UTC | VERACYTE, INC. VCYT · Entity 2018 | SaleCommon Stock | 7,441 | $30.19 | $224,616.26 |
DisclosureSEC source: 0001384101-23-000130 · wk-form4_1689813200.xml · nonDerivative · entry 4 JONES EVAN/ FA · CIK 0001020741 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · by jVen Capital, LLC Disclosed balance after: 38,263 F7 · price: Represents weighted average sales price. Sale prices for the transactions range from $30.00 to $30.46. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. F3 · acquired: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on December 12, 2022. F5 · ownership.nature: The Reporting Person is the sole managing member of jVen Capital, LLC. Read SEC document |
| July 18, 2023 Filed Jul 20, 2023 00:33 UTC | VERACYTE, INC. VCYT · Entity 2018 | SaleCommon Stock | 2,324 | $30.16 | $70,089.75 |
DisclosureSEC source: 0001384101-23-000130 · wk-form4_1689813200.xml · nonDerivative · entry 3 JONES EVAN/ FA · CIK 0001020741 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,439 F6 · price: Represents weighted average sales price. Sale prices for the transactions range from $30.00 to $30.42. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. F1 · acquired: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on June 11, 2022. Read SEC document |
| July 17, 2023 Filed Jul 20, 2023 00:33 UTC | VERACYTE, INC. VCYT · Entity 2018 | SaleCommon Stock | 23,949 | $30.07 | $720,105.72 |
DisclosureSEC source: 0001384101-23-000130 · wk-form4_1689813200.xml · nonDerivative · entry 2 JONES EVAN/ FA · CIK 0001020741 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · by jVen Capital, LLC Disclosed balance after: 45,704 F4 · price: Represents weighted average sales price. Sale prices for the transactions range from $30.00 to $30.24. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. F3 · acquired: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on December 12, 2022. F5 · ownership.nature: The Reporting Person is the sole managing member of jVen Capital, LLC. Read SEC document |
| July 17, 2023 Filed Jul 20, 2023 00:33 UTC | VERACYTE, INC. VCYT · Entity 2018 | SaleCommon Stock | 19,095 | $30.07 | $574,106.45 |
DisclosureSEC source: 0001384101-23-000130 · wk-form4_1689813200.xml · nonDerivative · entry 1 JONES EVAN/ FA · CIK 0001020741 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,763 F2 · price: Represents weighted average sales price. Sale prices for the transactions range from $30.00 to $30.22. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. F1 · acquired: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on June 11, 2022. Read SEC document |
| June 09, 2023 Filed Jun 13, 2023 21:21 UTC | VERACYTE, INC. VCYT · Entity 2018 | GrantCommon Stock | 9,674 | $0.00 | $0.00 |
DisclosureSEC source: 0001384101-23-000124 · wf-form4_168669130193468.xml · nonDerivative · entry 1 JONES EVAN/ FA · CIK 0001020741 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 59,858 F1 · kind: Restricted stock units awarded on June 9, 2023 vest in full on the first anniversary of the date of the grant or immediately prior to the Company's next annual meeting of stockholders, if earlier. In addition, the restricted stock units vest in full in the event of a change in control of the Issuer. Read SEC document |
| December 14, 2022 Filed Dec 16, 2022 22:04 UTC | VERACYTE, INC. VCYT · Entity 2018 | SaleCommon Stock | 600 | $30.13 | $18,080.16 |
DisclosureSEC source: 0001384101-22-000166 · wf-form4_167122823938243.xml · nonDerivative · entry 1 JONES EVAN/ FA · CIK 0001020741 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,184 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on June 11, 2022. F2 · price: Represents weighted average sales price. Sale prices for the transactions range from $30.02 to $30.51. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. Read SEC document |
| December 13, 2022 Filed Dec 15, 2022 22:00 UTC | VERACYTE, INC. VCYT · Entity 2018 | SaleCommon Stock | 300 | $31.65 | $9,493.50 |
DisclosureSEC source: 0001384101-22-000164 · wf-form4_167114160864923.xml · nonDerivative · entry 2 JONES EVAN/ FA · CIK 0001020741 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,784 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on June 11, 2022. F3 · price: Represents weighted average sales price. Sale prices for the transactions range from $31.465 to $31.91. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. Read SEC document |
| December 13, 2022 Filed Dec 15, 2022 22:00 UTC | VERACYTE, INC. VCYT · Entity 2018 | SaleCommon Stock | 1,367 | $30.51 | $41,703.21 |
DisclosureSEC source: 0001384101-22-000164 · wf-form4_167114160864923.xml · nonDerivative · entry 1 JONES EVAN/ FA · CIK 0001020741 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,084 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on June 11, 2022. F2 · price: Represents weighted average sales price. Sale prices for the transactions range from $30.06 to $31.05. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. Read SEC document |
| November 11, 2022 Filed Nov 15, 2022 21:54 UTC | VERACYTE, INC. VCYT · Entity 2018 | SaleCommon Stock | 100 | $31.02 | $3,102.03 |
DisclosureSEC source: 0001384101-22-000143 · wf-form4_166854926790911.xml · nonDerivative · entry 2 JONES EVAN/ FA · CIK 0001020741 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,451 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on June 11, 2022. F3 · price: Represents weighted average sales price. Sale prices for the transactions range from $31.02 to $31.03. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.